BioClinica, Inc., a global provider of clinical trial services, has signed a three-year, multi-million dollar deal with Cephalon, Inc. for clinical trial technology and support services. As part of the Service Agreement, US-based data management staff at Cephalon will be hired by BioClinica to support clinical efforts of Cephalon.
BioClinica will provide end-to-end clinical data management services to Cephalon global clinical trial operations. Specific tasks include data management planning, clinical study set-up for electronic data capture (EDC), medical coding, adverse event reconciliation, clinical data management, and training for the clinical sites and investigators. The deal also expands plans by Cephalon to use BioClinica’s ExpressTM electronic data capture (EDC) product as the default data capture system across clinical trial phases, from Phases I through IV. BioClinica will work with other functional service providers selected as part of Cephalon’s initiative to optimize operational efficiency. BioClinica said it will see its role with Cephalon extended from one of a technology provider to that of a “key services partner”.
Mark Weinstein, President and CEO of BioClinica said: "We will help Cephalon centralize and streamline its clinical data management operations through improved process standardization, consistency of delivery, economies of scale and cost savings. There are other technology players out there and certainly no shortage of service-based CROs, but BioClinica is the only organization that successfully blends those models into a true eClinical suite." The two firms have worked together since 2003 when Cephalon began using Phoenix Data Systems for electronic data capture. Phoenix Data Systems is now the core of BioClinica’s eClinical division.
“Our long-standing relationship with BioClinica supported our analysis that they were the best partner to deliver clinical data management services for us. The agreement was cemented on the shared philosophy that technology-smart people are key for the optimization of our global clinical development process,” said Dr. Charles Morris, Vice President of Worldwide Clinical Research at Cephalon.